Long-term outcomes and quality of life following implementation of dedicated mitral valve Heart Team decisions for patients with severe mitral valve regurgitation in tertiary cardiovascular care center
BACKGROUND: This study was purposed to investigate which treatment strategy was associated with the most favourable prognosis for patients with severe mitral regurgitation (MR) following Heart Team (HT)-decisions implementation.
METHODS: In this retrospective study, long-term outcomes of patients with severe MR qualified after HT discussion to: optimal medical treatment (OMT) alone, OMT and MitraClip (MC) procedure or OMT and mitral valve replacement (MVR) were evaluated. The primary endpoint was defined as cardiovascular (CV) death and the secondary endpoints included all-cause mortality, myocardial infarctions (MI), strokes, hospitalizations for heart failure exacerbation and CV events during a mean (standard deviation [SD]) follow-up of 29 (15) months.
RESULTS: From 2016 to 2019, 176 HT meetings were held and a total of 157 participants (mean age [SD] = 71.0 [9.2], 63.7% male) with severe MR and completely implemented HT decisions (OMT, MC or MVR for 53, 58 and 46 patients, respectively) were included into final analysis. Comparing OMT, MC and MVR groups statistically significant differences between the implemented procedures and occurrence of primary and secondary endpoints with the most frequent in OMT-group were observed (p < 0.05). However, for interventional strategy MC was non-inferior to MVR for all endpoints (p > 0.05). General health status assessed at the end of follow-up were significantly the lowest for MVR, then for MC and the highest for OMT-group (p < 0.01).
CONCLUSIONS: In the present study it was demonstrated that after careful HT evaluation of patients with severe MR at high risk of surgery, percutaneous strategy (MC) can be considered as equivalent to surgical treatment (MVR) with non-inferior outcomes.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:31 |
|---|---|
| Enthalten in: |
Cardiology journal - 31(2024), 1 vom: 09., Seite 62-71 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jonik, Szymon [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Heart Team |
|---|
| Anmerkungen: |
Date Completed 05.03.2024 Date Revised 09.03.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.5603/CJ.a2022.0011 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM338162755 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM338162755 | ||
| 003 | DE-627 | ||
| 005 | 20240309231830.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.5603/CJ.a2022.0011 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1321.xml |
| 035 | |a (DE-627)NLM338162755 | ||
| 035 | |a (NLM)35285514 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jonik, Szymon |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long-term outcomes and quality of life following implementation of dedicated mitral valve Heart Team decisions for patients with severe mitral valve regurgitation in tertiary cardiovascular care center |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.03.2024 | ||
| 500 | |a Date Revised 09.03.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a BACKGROUND: This study was purposed to investigate which treatment strategy was associated with the most favourable prognosis for patients with severe mitral regurgitation (MR) following Heart Team (HT)-decisions implementation | ||
| 520 | |a METHODS: In this retrospective study, long-term outcomes of patients with severe MR qualified after HT discussion to: optimal medical treatment (OMT) alone, OMT and MitraClip (MC) procedure or OMT and mitral valve replacement (MVR) were evaluated. The primary endpoint was defined as cardiovascular (CV) death and the secondary endpoints included all-cause mortality, myocardial infarctions (MI), strokes, hospitalizations for heart failure exacerbation and CV events during a mean (standard deviation [SD]) follow-up of 29 (15) months | ||
| 520 | |a RESULTS: From 2016 to 2019, 176 HT meetings were held and a total of 157 participants (mean age [SD] = 71.0 [9.2], 63.7% male) with severe MR and completely implemented HT decisions (OMT, MC or MVR for 53, 58 and 46 patients, respectively) were included into final analysis. Comparing OMT, MC and MVR groups statistically significant differences between the implemented procedures and occurrence of primary and secondary endpoints with the most frequent in OMT-group were observed (p < 0.05). However, for interventional strategy MC was non-inferior to MVR for all endpoints (p > 0.05). General health status assessed at the end of follow-up were significantly the lowest for MVR, then for MC and the highest for OMT-group (p < 0.01) | ||
| 520 | |a CONCLUSIONS: In the present study it was demonstrated that after careful HT evaluation of patients with severe MR at high risk of surgery, percutaneous strategy (MC) can be considered as equivalent to surgical treatment (MVR) with non-inferior outcomes | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Heart Team | |
| 650 | 4 | |a MitraClip | |
| 650 | 4 | |a heart failure | |
| 650 | 4 | |a mitral regurgitation | |
| 650 | 4 | |a mitral valve replacement | |
| 700 | 1 | |a Marchel, Michał |e verfasserin |4 aut | |
| 700 | 1 | |a Pędzich-Placha, Ewa |e verfasserin |4 aut | |
| 700 | 1 | |a Pietrasik, Arkadiusz |e verfasserin |4 aut | |
| 700 | 1 | |a Rdzanek, Adam |e verfasserin |4 aut | |
| 700 | 1 | |a Huczek, Zenon |e verfasserin |4 aut | |
| 700 | 1 | |a Kochman, Janusz |e verfasserin |4 aut | |
| 700 | 1 | |a Budnik, Monika |e verfasserin |4 aut | |
| 700 | 1 | |a Piątkowski, Radosław |e verfasserin |4 aut | |
| 700 | 1 | |a Scisło, Piotr |e verfasserin |4 aut | |
| 700 | 1 | |a Kochanowski, Janusz |e verfasserin |4 aut | |
| 700 | 1 | |a Czub, Paweł |e verfasserin |4 aut | |
| 700 | 1 | |a Wilimski, Radosław |e verfasserin |4 aut | |
| 700 | 1 | |a Hendzel, Piotr |e verfasserin |4 aut | |
| 700 | 1 | |a Grabowski, Marcin |e verfasserin |4 aut | |
| 700 | 1 | |a Filipiak, Krzysztof J |e verfasserin |4 aut | |
| 700 | 1 | |a Opolski, Grzegorz |e verfasserin |4 aut | |
| 700 | 1 | |a Mazurek, Tomasz |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cardiology journal |d 2007 |g 31(2024), 1 vom: 09., Seite 62-71 |w (DE-627)NLM181132737 |x 1898-018X |7 nnns |
| 773 | 1 | 8 | |g volume:31 |g year:2024 |g number:1 |g day:09 |g pages:62-71 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.5603/CJ.a2022.0011 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 31 |j 2024 |e 1 |b 09 |h 62-71 | ||